object
date
definit
cutoff
valu
cytomegaloviru
cmv
dna
load
bronchoalveolar
lavag
bal
fluid
specimen
establish
discrimin
cmv
pneumonia
pulmonari
cmv
dna
shed
allogen
hematopoiet
stem
cell
transplant
allohsct
recipi
method
current
retrospect
studi
aim
assess
rang
cmv
dna
load
quantifi
bal
fluid
specimen
allohsct
patient
pneumonia
differ
microorgan
causal
involv
result
total
bal
specimen
patient
includ
cmv
dna
detect
bal
fluid
specimen
median
cmv
dna
load
patient
cmv
pneumonia
unlik
could
tent
rule
iuml
frequenc
cmv
dna
detect
median
cmv
dna
load
compar
irrespect
attribut
caus
pneumonia
detect
cmv
dna
load
bal
fluid
specimen
iuml
independ
associ
pneumoniaattribut
mortal
conclus
current
studi
highlight
difficulti
establish
univers
cmv
dna
load
threshold
bal
fluid
specimen
distinguish
cmv
pneumonia
pulmonari
cmv
dna
shed
suggest
presenc
cmv
dna
bal
fluid
specimen
beyond
certain
level
may
deleteri
impact
patient
outcom
implement
effect
prevent
strategi
significantli
reduc
incid
cytomegaloviru
cmv
pneumonia
allogen
hematopoiet
stem
transplant
allohsct
nevertheless
clinic
entiti
persist
major
clinic
problem
owe
poor
surviv
despit
time
initi
target
antivir
therapi
current
diagnosi
cmv
pneumonia
still
remain
challeng
proven
cmv
pneumonia
diagnos
use
virolog
histopatholog
immunochemistri
method
biopsi
lung
tissu
specimen
type
howev
rare
obtain
due
potenti
lifethreaten
complic
tradit
culturebas
bronchoalveolar
lavag
bal
test
mainstay
suggest
cmv
involv
ex
vivo
although
detect
viabl
cmv
bal
fluid
point
probabl
causal
may
present
absenc
probabl
proven
diseas
pulmonari
cmv
shed
recent
studi
suggest
quantit
cmv
dna
bal
fluid
may
permit
discrimin
two
condit
specif
cutoff
cmv
dna
level
iuml
propos
serv
purpos
display
posit
predict
valu
roughli
probabl
cmv
pneumonia
use
current
preval
rate
nevertheless
valid
diagnost
viral
load
threshold
across
center
use
differ
realtim
pcr
assay
cmv
dna
quantit
procedur
bal
obtent
seem
paramount
relev
task
hamper
low
incid
cmv
pneumonia
nowaday
difficulti
establish
incontrovert
diagnosi
even
lung
tissu
specimen
avail
test
exploratori
studi
gather
inform
rang
cmv
dna
load
measur
bal
specimen
allohsct
patient
pneumonia
cmv
causal
unlik
reason
rule
may
provid
use
inform
thu
warrant
report
experi
matter
studi
cohort
consist
consecut
patient
receiv
allohsct
hospit
universitariohcu
n
hospit
universitario
la
fe
hlf
n
underw
diagnost
bronchoscopi
clinic
microbiolog
data
patient
bal
fluid
specimen
n
hcu
n
hlf
n
submit
respect
microbiolog
servic
may
may
respect
retrospect
review
per
protocol
quantit
cmv
pcr
test
routin
perform
bal
specimen
center
sinc
patient
clinic
radiographi
sign
pneumonia
time
sampl
bronchoscopi
perform
use
standard
procedur
accord
intern
consensu
guidelin
first
bal
fluid
specimen
per
pneumonia
event
taken
consider
analysi
purpos
studi
approv
hospit
incliva
ethic
committe
inform
consent
obtain
patient
preemptiv
antivir
therapi
approach
use
hcu
prevent
cmv
endorgan
diseas
cmv
dna
plasma
quantifi
use
realti
cmv
pcr
assay
abbott
molecular
de
plain
il
usa
exhibit
limit
detect
approxim
iuml
patient
preemptiv
treat
oral
valganciclovir
iv
ganciclovir
iv
foscarnet
upon
detect
cmv
dna
level
exceed
iuml
cmv
dna
doubl
time
day
previous
report
surveil
cmv
dna
detect
quantit
conduct
least
week
within
first
day
allohsct
extend
beyond
day
patient
risk
recurr
episod
cmv
dnaemia
turn
univers
prophylaxi
strategi
deploy
hlf
briefli
hlamatch
relat
allohsct
recipi
given
oral
valganciclovir
mgday
three
time
week
day
transplant
unrel
allohsct
recipi
treat
oral
valganciclovir
mgday
day
transplant
center
plasma
cmv
dna
load
quantifi
use
cmv
biomerieux
letoil
pari
franc
display
limit
detect
iuml
prior
dna
extract
use
viruspathogen
mini
kit
qiagen
valencia
ca
usa
qiasymphoni
dsp
platform
qiagen
plasma
cmv
dna
monitor
perform
week
within
first
day
fortnightli
day
day
everi
week
thereaft
day
transplant
detect
level
cmv
dna
plasma
prompt
administr
antivir
therapi
val
ganciclovir
foscarnet
dose
specifi
anticmv
therapi
given
physician
discret
patient
cmv
dna
detect
bal
specimen
concurr
cmv
dnaemia
cmv
dna
level
threshold
preemptiv
antivir
therapi
plasma
specimen
obtain
within
h
bal
sampl
avail
patient
cmv
dna
quantit
bal
fluid
specimen
underw
cmv
pcr
test
within
h
upon
recept
sampl
kept
process
bal
fluid
specimen
obtain
differ
locat
avail
collect
steril
contain
pool
vortex
addit
steril
glass
bead
twohundr
undilut
bal
fluid
sampl
subject
nucleic
acid
extract
use
sp
system
abbott
diagnost
qiaamp
dna
blood
mini
kit
qiagen
either
qia
symphoni
platform
qiagen
cmv
dna
quantit
perform
use
realti
cmv
pcr
assay
abbott
molecular
hcu
cmv
assay
biomerieux
hlf
commut
cmv
intern
standard
cmv
dna
quantit
bal
specimen
assess
cmv
standard
reconstitut
ml
deioniz
water
recommend
manufactur
pool
bal
specimen
free
cmv
dna
determin
abbott
pcr
assay
made
spike
intern
standard
predefin
cmv
dna
concentr
achiev
nomin
valu
iuml
refer
materi
assay
triplic
singl
run
cmv
dna
level
measur
bal
fluid
specimen
close
match
expect
mean
standard
deviat
pcr
assay
log
iuml
cmv
standard
concentr
test
gram
stain
fungal
stain
acidfast
bacilli
stain
routin
perform
cytolog
examin
bal
fluid
cytospin
perform
systemat
patient
attend
hcu
nonroutin
hlf
bal
fluid
cytospin
data
avail
patient
addit
bal
fluid
specimen
examin
presenc
respiratori
virus
rv
use
either
luminex
xtag
rvp
fast
assay
luminex
molecular
diagnost
austin
tx
usa
hcu
allow
detect
rv
pneumovir
assay
genomica
coslada
spain
centersthat
make
possibl
detect
simultan
rv
previous
report
quantit
cultur
bal
specimen
bacteri
isol
perform
convent
media
recommend
bacteri
load
cfuml
deem
clinic
relev
bal
specimen
cultur
bcyealpha
agar
bd
becston
dickinson
mycobacteria
growth
indic
tube
lowensteinjensen
agar
slant
sabouraud
agar
recoveri
legionella
pneumophila
mycobacterium
spp
fungal
organ
respect
platelia
tm
aspergillu
ag
kit
biorad
hercul
ca
usa
use
quantit
aspergillu
spp
galactomannan
bal
fluid
serum
specimen
calcofluor
white
blue
toluidin
direct
immunofluoresc
stain
procedur
use
detect
pneumocysti
jiroveci
lung
biopsi
tissu
specimen
obtain
likewis
neither
shell
vial
convent
viral
cultur
cmv
detect
recoveri
direct
fluoresc
antibodi
test
cmv
detect
perform
acyclovirvalacyclovir
prophylaxi
herp
simplex
varicella
zoster
virus
given
patient
previous
describ
patient
receiv
standard
antibacteri
antifung
prophylaxi
definit
cmv
dnaemia
pulmonari
cmv
dna
shed
defin
detect
cmv
dna
level
one
plasma
bal
fluid
specimen
respect
proven
cmv
pneumonia
categor
requir
histopatholog
evid
ie
viral
inclus
immunohistochem
stain
biopsi
autopsi
lung
tissu
cmv
pneumonia
diagnosi
reason
exclud
cmvinduc
cytopathogenet
effect
observ
postmortem
autopsi
lung
tissu
data
avail
patient
bal
fluid
cytospin
data
avail
patient
lack
chest
x
ray
comput
tomographi
ct
evid
consist
cmv
pneumonia
ie
reticulonodular
infiltr
presenc
bilater
groundglass
opac
airspac
opac
small
centrilobular
nodul
cm
absenc
larger
nodul
see
review
altern
diagnos
could
account
sign
symptom
particularli
presenc
signific
bacteri
viru
fungal
pathogen
demonstr
clinic
radiograph
respons
target
antimicrobi
therapi
bacteri
fungal
noncmv
viral
infect
also
consid
involv
cmv
probabl
cmv
pneumonia
categori
accord
recent
criteria
consid
herein
sinc
culturebas
bal
fluid
test
perform
diagnost
cmv
dna
cutoff
level
definit
establish
diagnosi
proven
probabl
possibl
invas
fungal
infect
pneumocysti
jiroveci
pneumonia
achiev
follow
consensu
criteria
acut
graft
versu
host
diseas
agvhd
diagnos
grade
accord
standard
criteria
frequenc
compar
use
test
fisher
exact
test
categor
variabl
differ
median
compar
use
mannwhitney
u
test
two
independ
variabl
kruskalw
test
two
independ
variabl
cumul
incid
plot
mortal
pneumonia
gener
graphpad
prism
softwar
la
jolla
ca
usa
curv
compar
use
gehanwilcoxon
test
cox
proport
hazard
model
use
evalu
unadjust
adjust
hazard
ratio
ahr
mortal
attribut
pneumonia
previous
report
multivari
analys
variabl
paramet
estim
show
p
valu
univari
analys
includ
twosid
exact
p
valu
report
p
valu
consid
statist
signific
data
analyz
spss
version
statist
packag
tabl
show
relev
demograph
clinic
characterist
patient
cohort
bal
fluid
sampl
obtain
median
day
allohsct
rang
day
five
year
specif
detail
microbiolog
yield
bal
fluid
specimen
shown
tabl
proven
cmv
pneumonia
diagnos
patient
basi
histopatholog
immunohistochemistri
find
lung
autopsi
tissu
remain
episod
pneumonia
attribut
bacteria
case
one
virus
invas
aspergillosi
infect
case
categor
possibl
n
probabl
n
proven
n
mix
infect
document
patient
individu
pathogenet
contribut
detect
cultur
microbi
agent
pneumonia
attempt
settl
twentythre
pneumonia
case
deem
infecti
caus
basi
clinic
radiograph
data
lack
detect
potenti
pathogen
microorgan
cmv
bal
fluid
specimen
cmv
dna
detect
bal
fluid
specimen
patient
pneumonia
episod
potenti
respiratori
pathogen
one
either
cultur
detect
case
deem
infecti
origin
latter
case
involv
cmv
caus
agent
reason
rule
clinic
radiograph
ground
cmv
dna
present
bal
fluid
specimen
two
patient
proven
cmv
pneumonia
microorgan
concurr
detectedcultur
two
specimen
frequenc
cmv
dna
detect
compar
p
regardless
establish
presum
etiolog
pneumonia
tabl
episod
cmv
dna
bal
detect
occur
face
ongo
episod
cmv
dnaemia
includ
two
episod
occur
set
autopsyproven
cmv
pneumon
isol
remain
episod
clinic
laboratori
characterist
patient
n
cmv
dna
codetect
bal
plasma
specimen
absenc
presum
cmv
pneumon
n
episod
merit
special
attent
cmv
lung
diseas
usual
occur
concomitantli
cmv
dnaemia
data
shown
supplementari
tabl
cmv
pneumon
deem
unlik
patient
owe
one
follow
lack
typic
find
ct
episod
ii
neg
bal
cytospin
result
episod
iii
neg
lung
histopatholog
autopsi
tabl
pneumonia
attribut
etiolog
microbiolog
find
bronchoalveolar
lavag
fluid
specimen
c
accord
accord
e
includ
idiopath
pneumonia
syndrom
bronchiol
obliteran
cryptogen
organ
pneumonia
among
caus
patient
die
iv
surviv
patient
undergo
specif
anticmv
treatment
cours
appropri
dose
cmv
pneumon
episod
note
patient
seri
treat
anticmv
drug
cmv
pneumon
recommend
v
document
presenc
bacteria
virus
cmv
fungal
pathogen
known
caus
pneumonia
episod
vi
clinic
respons
surviv
target
antibacteri
antivir
influenza
viru
antifung
therapi
episod
nevertheless
particular
four
episod
caus
involv
cmv
rais
doubt
second
episod
patient
episod
patient
tabl
despit
fact
ct
scan
suggest
cmv
pneumon
altern
microbi
etiolog
document
patient
die
pneumonia
attribut
caus
death
addit
cmv
dna
detect
high
level
bal
rang
iuml
plasma
rang
iuml
specimen
one
patient
patient
neg
bal
cytospin
result
turn
cmv
dnaemia
document
case
absenc
cmv
dna
detect
bal
fluid
sampl
recipi
cmv
seroposit
treatment
corticosteroid
associ
detect
cmv
dna
bal
fluid
specimen
univari
analys
supplementari
tabl
overal
median
cmv
dna
load
bal
fluid
specimen
patient
categor
cmv
pneumonia
iuml
rang
iuml
magnitud
greater
p
specimen
analyz
hlf
median
iuml
rang
iuml
test
hcu
median
iuml
rang
iuml
supplementari
fig
cmv
dna
load
iuml
pneumonia
episod
iuml
remain
tabl
cmv
dna
load
bal
fluid
two
proven
cmv
pneumonia
case
iuml
trend
toward
higher
cmv
dna
load
bal
fluid
specimen
observ
p
episod
cmv
dnaemia
detect
concurr
iuml
rang
iuml
vs
iuml
rang
iuml
absenc
cmv
dna
load
bal
fluid
specimen
compar
p
irrespect
etiolog
attribut
pneumonia
fig
supplementari
tabl
overal
trend
toward
invers
correl
level
immunosuppress
infer
immunodefici
index
isi
see
footnot
tabl
cmv
dna
load
quantifi
bal
specimen
rho
p
overal
patient
anticmv
therapi
time
bal
sampl
prophylaxi
n
preemptiv
therapi
n
among
cmv
dna
detect
bal
fluid
receiv
anticmv
therapi
preemptiv
therapi
n
antivir
prophylaxi
n
cmv
dna
load
bal
significantli
higher
patient
antivir
therapi
median
iuml
rang
iuml
vs
median
iuml
rang
iuml
p
nontreat
patient
two
patient
cmv
dna
detect
bal
fluid
concurr
cmv
dnaemia
treat
iv
ganciclovir
fortysix
patient
die
within
day
bal
sampl
includ
one
patient
proven
cmv
pneumonia
caus
death
deem
relat
pneumonia
episod
patient
cumul
incid
pneumoniaattribut
mortal
compar
across
differ
etiolog
categori
fig
investig
whether
presenc
cmv
dna
bal
fluid
specimen
associ
increas
mortal
found
case
nevertheless
roc
curv
analysi
enabl
determin
cutoff
cmv
dna
level
bal
fluid
identifi
patient
increas
mortal
threshold
iuml
sensit
ci
specif
ci
supplementari
fig
adjust
cox
model
includ
addit
variabl
number
other
could
impact
pneumoniaattribut
mortal
identifi
detect
cmv
dna
load
bal
fluid
specimen
level
iuml
treatment
corticosteroid
dose
lymphocyt
count
l
b
cutoff
establish
roc
analysi
shown
cumul
incid
mortal
attribut
pneumonia
complic
day
bronchoalveolar
lavag
fluid
test
accord
etiolog
cumul
incid
plot
gener
graphpad
prism
softwar
la
jolla
ca
usa
curv
compar
use
gehanwilcoxon
test
p
valu
shown
latter
two
time
bal
sampl
paramet
independ
associ
pneumoniaattribut
mortal
tabl
moreov
shown
fig
factor
appear
exert
synergist
impact
mortal
definit
abandon
tradit
culturebas
procedur
cmv
test
laboratori
nonavail
lung
biopsi
specimen
histopatholog
immunohistochemistri
examin
make
diagnosi
proven
probabl
cmv
pneumonia
elus
nowaday
moreov
cutoff
valu
cmv
dna
load
bal
fluid
specimen
discrimin
cmv
pneumonia
pulmonari
cmv
dna
shed
allohsct
recipi
establish
present
time
assess
perform
quantit
cmv
dna
pcr
test
diagnosi
cmv
pneumonia
face
sever
difficulti
includ
low
incid
clinic
event
ii
lack
normal
procedur
cmv
dna
pcr
test
bal
fluid
iii
nonneglig
possibl
miscategor
pneumonia
case
either
causal
link
unrel
cmv
use
bal
fluid
specimen
even
lung
tissu
materi
cmv
diagnosi
iv
persist
larg
variabl
cmv
dna
load
provid
differ
realtim
pcr
assay
despit
calibr
intern
standard
cmv
dna
alreadi
mention
v
releg
virolog
procedur
cmv
detect
clinic
specimen
inevit
drawback
encount
studi
aim
establish
diagnost
cutoff
rather
assess
rang
cmv
dna
load
quantifi
bal
fluid
specimen
patient
causal
involv
cmv
highli
unlik
could
reason
discard
mind
sure
incur
cmv
pneumonia
infradiagnosi
nevertheless
perceiv
limit
insoslay
obstacl
purpos
fig
cumul
incid
mortal
attribut
pneumonia
complic
day
bronchoalveolar
lavag
fluid
test
accord
presenc
one
factor
associ
mortal
multivari
cox
model
cmv
dna
load
bal
fluid
iuml
treatment
corticosteroid
total
lymphocyt
count
l
cumul
incid
plot
gener
graphpad
prism
softwar
la
jolla
ca
usa
curv
compar
use
gehanwilcoxon
test
p
valu
comparison
shown
cmv
unlik
etiolog
agent
pneumonia
case
among
allohsct
recipi
undergo
routin
bronchoscopi
ii
surviv
patient
cmv
pneumonia
undergo
specif
anticmv
treatment
appropri
dose
val
ganciclovir
foscarnet
highli
unlik
provid
high
rate
cmv
pneumoniaassoci
mortal
retrospect
review
clinic
microbiolog
data
patient
underw
routin
quantit
cmv
pcr
test
bal
fluid
specimen
two
transplant
center
citi
deliber
chose
includ
archiv
bal
specimen
seri
lack
data
impact
cryopreserv
cmv
dna
load
quantit
sampl
type
sever
find
aros
present
studi
first
confirm
previou
observ
indic
detect
cmv
dna
bal
fluid
specimen
use
highlysensit
pcr
assay
common
find
allohsct
patient
pneumonia
irrespect
definit
etiolog
diagnosi
seri
cmv
dna
detect
one
third
bal
fluid
sampl
frequenc
detect
vari
patient
seemingli
infecti
pneumonia
patient
mix
infect
seri
recipi
cmv
seroposit
treatment
corticosteroid
associ
detect
cmv
bal
fluid
specimen
interest
two
patient
proven
cmv
pneumonia
cmv
dna
detect
bal
fluid
second
found
wide
rang
cmv
dna
load
measur
bal
fluid
specimen
patient
pneumonia
cmv
causal
unlik
reason
rule
attend
clinic
includ
therapeut
respons
nonanticmv
drug
radiograph
lung
autopsi
histopatholog
bal
fluid
cytolog
patient
microbiolog
criteria
interestingli
median
cmv
dna
load
compar
irrespect
natur
number
codetect
microorgan
particip
center
overal
higher
presenc
concurr
dnaemia
latter
observ
agreement
boeckh
et
al
found
due
pulmonari
hemorrhag
shown
overal
cmv
dna
load
bal
fluid
specimen
process
hlf
greater
magnitud
analyz
hcu
sinc
cmv
dna
load
produc
argen
pcr
assay
slightli
lower
measur
abbott
pcr
assay
shown
differ
net
state
immunosuppress
patient
time
bal
sampl
across
center
reflect
immunodefici
score
index
higher
hlf
patient
may
account
observ
fact
trend
toward
invers
correl
found
isi
score
cmv
dna
load
quantifi
bal
specimen
recent
studi
cmv
dna
load
cutoff
iuml
bal
fluid
found
posit
predict
valu
presenc
probabl
cmv
pneumonia
consid
preval
event
among
patient
risk
undergo
bal
test
tan
et
al
contrast
found
cmv
dna
level
bal
fluid
sampl
limit
valu
distinguish
cmv
noncmv
pneumonia
case
pertin
mention
threshold
one
two
log
lower
tent
propos
diagnos
cmv
pneumonia
lung
transplant
recipi
interestingli
control
patient
noncmv
pneumonia
boeckh
studi
show
median
cmv
dna
load
log
iuml
iqr
iuml
cmv
dna
level
iuml
roughli
case
iuml
opposit
true
nearli
bal
fluid
sampl
patient
nonproven
cmv
pneumonia
cmv
viral
load
iuml
iuml
worth
highlight
figur
compar
particip
center
despit
aboveref
differ
cmv
dna
load
provid
pcr
assay
use
center
gaug
potenti
relev
data
must
taken
consider
nearli
pneumonia
episod
cohort
bal
sampl
perform
patient
anticmv
therapi
day
wherea
aforement
studi
patient
cmv
pneumonia
patient
noncmv
pneumonia
treat
antivir
least
two
day
despit
fact
higher
cmv
dna
load
bal
fluid
specimen
quantifi
current
studi
like
reflect
major
differ
regard
dnaemia
cutoff
trigger
incept
antivir
therapi
studi
much
higher
current
cohort
fact
seri
median
cmv
dna
load
bal
significantli
higher
patient
antivir
therapi
nontreat
patient
state
limit
number
proven
cmv
pneumonia
case
seri
preclud
attempt
establish
diagnost
cmv
dna
load
cutoff
nevertheless
light
data
present
herein
threshold
valu
iuml
unlik
discrimin
cmv
pneumonia
pulmonari
cmv
dna
shed
set
sens
fulli
support
idea
magnitud
diagnost
cutoff
like
vari
depend
upon
patient
characterist
bal
procedur
process
assay
use
cmv
dna
quantit
sever
cmv
pneumonia
time
sampl
data
interpret
caution
exclus
cmv
probabl
caus
agent
judg
dubiou
case
provid
virolog
method
use
investig
presenc
cmv
bal
fluid
specimen
particular
episod
occur
patient
die
cmv
dna
detect
high
level
bal
plasma
specimen
iuml
altern
microbi
etiolog
document
nevertheless
conclus
drawn
basi
overal
dataset
stood
case
littl
doubt
exist
lack
involv
cmv
ie
bacteri
pneumonia
tuberculosi
analyz
separ
repres
exampl
shown
supplementari
tabl
cmv
highli
proinflammatori
immunosuppress
viru
may
act
synergist
copathogen
absenc
document
cmvinduc
cytopathogen
may
relev
impact
patient
outcom
sens
found
presenc
cmv
dna
bal
fluid
specimen
level
iuml
addit
receipt
corticosteroid
low
lymphocyt
count
time
bal
sampl
associ
increas
pneumoniaattribut
mortal
cox
multivari
model
rel
scarc
number
pneumonia
case
bal
specimen
cmv
dna
load
iuml
allow
investig
whether
appar
effect
exhibit
doserespons
pattern
find
must
interpret
cautious
order
avoid
overfit
cox
model
adjust
number
factor
may
impact
mortal
ie
adequaci
antimicrobi
treatment
sever
pneumonia
among
other
limit
size
current
cohort
also
preclud
meaning
statist
analysi
evalu
impact
cmv
dna
load
bal
center
separ
studi
urgent
need
valid
observ
sinc
subset
patient
may
benefit
short
cours
anticmv
therapi
limit
current
studi
addit
one
highlight
retrospect
natur
potenti
bias
select
patient
requir
bronchoscopi
etiolog
diagnosi
pneumonia
lack
normal
cmv
dna
load
bal
fluid
cellular
dna
content
although
report
expend
previou
studi
use
differ
dna
extract
platform
realtim
pcr
assay
cmv
dna
quantit
nevertheless
studi
sever
strength
includ
inclus
consecut
specimen
use
fresh
bal
fluid
specimen
highlysensit
realtim
pcr
assay
cmv
dna
load
quantit
perform
comprehens
systemat
evalu
specimen
presenc
rv
pathogen
use
molecular
assay
summari
studi
highlight
difficulti
establish
univers
cmv
dna
load
threshold
bal
fluid
specimen
distinguish
cmv
pneumonia
pulmonari
cmv
dna
shed
despit
potenti
impact
presenc
cmv
bal
fluid
specimen
pneumoniaattribut
mortal
observ
herein
merit
investig
end
larg
multicent
prospect
studi
use
consensu
protocol
cmv
dna
pcr
bal
test
convent
culturebas
virolog
test
may
shed
light
issu
